Search results
Q3 2025 EPS Estimates for Teva Pharmaceutical Industries Limited Boosted by Analyst (NYSE:TEVA)
ETF DAILY NEWS· 2 days agoTeva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) – Zacks Research lifted their Q3 2025 EPS estimates for shares of Teva Pharmaceutical Industries ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 4 days agoPharmaceutical Warehousing Market to Reach $39.00 Billion, Globally, by 2032 at 4.7% CAGR: Allied Market Research PR Newswire PORTLAND, Ore., May 2, 2024 Growth in the < ...
Why Investors Are Eyeing Regeneron Pharmaceuticals Inc (REGN): T
Guru Focus· 3 days agoRegeneron Pharmaceuticals Inc (REGN) has recently captured the attention of investors and financial analysts alike, thanks to its solid financial performance an
Here's What Analysts Are Forecasting For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its...
Simply Wall St. via Yahoo Finance· 2 days agoFactoring in the forecast slowdown in growth, it looks like Ultragenyx Pharmaceutical is forecast to...
Jazz Pharmaceuticals First Quarter 2024 Earnings: Misses Expectations
Simply Wall St. via Yahoo Finance· 3 days agoEarnings per share (EPS) was also behind analyst expectations. Looking ahead, revenue is forecast to...
Insider Sale at Vertex Pharmaceuticals Inc (VRTX): Director Sang
Guru Focus· 4 days agoVertex Pharmaceuticals Inc (VRTX, Financial) is a biotechnology firm focused on developing and commercializing therapies for the treatment of cystic fibrosis and other severe ...
Congratulations, you survived another tax season—and paid a higher rate than top American companies
Fortune via Yahoo Finance· 6 days agoBut far too many companies pay far less than this already low rate. Oxfam’s recent analysis of the...
Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 3 days agos R&D, presenting both opportunities and financial obligations. Regeneron's innovation in...
Earnings call: Amneal Pharmaceuticals sees robust growth in Q1 2024 By Investing.com
Investing.com· 2 days agoAmneal Pharmaceuticals, Inc. (NYSE: NASDAQ:AMRX) has reported a remarkable performance in the first...
Lyra Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Simply Wall St. via Yahoo Finance· 4 days agoEarnings per share (EPS) missed analyst estimates by 28%. Looking ahead, revenue is forecast to grow...